Schizophrenia Research
Schizophrenia is a chronic, debilitating mental disorder affecting 1-2% of the global population. Symptoms are split into two types; 'positive' symptoms, including delusions and hallucinations, and 'negative' symptoms, including anhedonia and lack of motivation. Studies suggest that genetics, early environment, neurobiology, psychological and social processes are important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Several neurobiological alterations in brain structure, physiology and neurochemistry have been documented, along with an ever-increasing list of susceptibility genes.
Schizophrenia Research Products Targets
- Others (13)
- Sigma2 Receptor (4)
- Sigma1 Receptor (16)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- GPR55 (8)
- CB2 Receptor (6)
- CB1 Receptor (17)
- Nicotinic (α7) Receptor (25)
- Nicotinic (α4β2) Receptor (14)
- D3 Receptor (12)
- NK3 Receptor (5)
- Carboxypeptidase (1)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Trace Amine 1 Receptor (2)
- Glutamate Transporter (18)
- Histamine H3 Receptor (22)
- Neurotensin Receptor (7)
- Monoamine Oxidase (10)
- iNOS (11)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
- Protein serine and threonine phosphatase (16)
- Protein Arginine Methyltransferase (2)
- Phosphodiesterase (34)
Products for Schizophrenia Research - Page 66
- Cat.No. Product Name Information/Activity
-
BCC6609
L-CCG-l
117857-93-9
-
BCC5691
DCG IV
DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1/5R=389/630 μM) and III receptors (IC50: mGlu4/6/7/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects.
-
BCC7614
LY 354740
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
-
BCC7368
LY 379268
Highly selective group II mGlu agonist
-
BCC7623
(±)-LY 395756
852679-66-4
-
BCC6758
MAP4
157381-42-5
-
BCC6925
(RS)-APICA
170847-18-4
-
BCC6871
EGLU
EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.
-
BCC1724
LY341495
LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50s of 2.9 nM, 10 nM, 170 nM for mGluR-2, mGluR-3, mGluR-8, respectively.
-
BCC6819
MSPG
169209-64-7


